Treatment
Capox clinical trials
We’re tracking 43 recruiting studies that include Capox, each written for real people, not researchers, below.
Recruiting studies
- NCT07528209RecruitingPhase 3
Chemotherapy with or without immunotherapy for advanced rectal cancer
This study tests whether adding an immunotherapy drug (pucotenlimab) to standard chemotherapy (CAPOX) before surgery helps treat locally advanced rectal cancer better. The goal is to shrink tumors and improve survival while preserving bowel function when possible.
Guangzhou, GuangdongAges 18–75 - NCT06462053RecruitingPhase 2
Short radiotherapy plus chemo and immunotherapy for early low rectal cancer
This study is testing whether a short course of radiation combined with chemotherapy and an immunotherapy drug works better than the standard longer radiation and chemotherapy for early-stage rectal cancer that is low in the rectum. The goal is to see if this shorter treatment can help patients avoid surgery or have a better outcome.
ShanghaiAges 18–75 - NCT05174169RecruitingPhase 2/Phase 3
Adjuvant colon chemotherapy guided by tumor DNA results
This trial tests whether treatment for colon cancer after surgery can be guided by a blood test that looks for leftover cancer signals (ctDNA). It may help some people choose stronger or different chemo based on whether ctDNA is found after surgery.
Birmingham, AlabamaAges 18 years+ - NCT05646511RecruitingPhase 3
New chemotherapy timing tests for locally advanced rectal cancer
This Phase 3 trial compares two chemotherapy combinations given with surgery for locally advanced rectal cancer. It aims to find out which approach works better and is safer for shrinking and controlling the cancer before or around the time of treatment.
ChibaAges 18 years+ - NCT06177041RecruitingPhase 3
M108 plus chemo for CLDN18.2-positive stomach cancer
This trial tests a new drug (M108) combined with standard chemotherapy (CAPOX) as a first treatment for people with advanced stomach or gastroesophageal junction cancer that has a specific protein called Claudin 18.2. The goal is to see if adding M108 helps improve outcomes compared to chemotherapy alone.
Beijing, Beijing MunicipalityAges 18–75 - NCT07284992RecruitingPhase 2
Comparing short vs long radiation with immunotherapy for rectal cancer
This trial tests whether a short course of radiation followed by an immunotherapy drug (PD-L1 inhibitor) plus chemotherapy works as well as or better than a longer radiation course for locally advanced rectal cancer. The goal is to shrink tumors before surgery.
Jinan, ShandongAges 18–80 - NCT07347951RecruitingPhase 2
New drug combo for rectal cancer patients who want to save their anus
This trial tests a combination of short-course radiation, chemotherapy, and two targeted drugs (Serplulimab and Bevacizumab) for people with a specific type of rectal cancer. It aims to see if this treatment can help shrink the tumor enough to avoid surgery and keep the anus.
Wenzhou, ZhejiangAges 18–75 - NCT07646639RecruitingPhase 2
Radiation, chemotherapy, and immunotherapy for advanced rectal cancer
This study tests a combination of radiation therapy, chemotherapy drugs (capecitabine and oxaliplatin), and two types of immunotherapy (a PD-1 blocker and IL-2) for locally advanced rectal cancer. The goal is to see if this combination helps shrink tumors and improve outcomes before surgery.
Nanjing, JiangsuAges 18–70 - NCT07686640RecruitingPhase 3
Short course radiation plus chemo with or without immunotherapy for rectal cancer
This trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard short-course radiation and chemotherapy improves outcomes in people with a common type of locally advanced rectal cancer (pMMR/MSS). It is for those with stage II or III cancer that has at least one high-risk feature and is within 12 cm of the anal verge.
Jinan, ShandongAges 18–75 - NCT07221357RecruitingPhase 2/Phase 3
Pumitamig plus chemo vs standard care for new colorectal cancer
This trial tests a new drug called Pumitamig combined with chemotherapy against standard bevacizumab plus chemotherapy for people with advanced colorectal cancer that cannot be surgically removed and hasn't been treated yet. The goal is to see which combination works better and is safer.
Tucson, ArizonaAges 18 years+ - NCT05534087RecruitingPhase 3
Blood test guided chemo after colon cancer surgery
This study tests whether giving additional (adjuvant) chemotherapy based on a special blood test—circulating tumor DNA (ctDNA)—can lower the risk of colon cancer coming back. It targets people with stage II–III colon cancer whose blood test is positive for minimal residual disease (MRD) after completing standard chemo.
BusanAges 19–75 - NCT06281405RecruitingPhase 2
CAPOX and immunotherapy with or without radiation for rectal cancer
This trial tests whether adding radiation therapy to a combination of chemotherapy (CAPOX) and an immunotherapy drug (PD-1 antibody) is more effective than the combination alone for people with locally advanced rectal cancer that is MSS (microsatellite stable) or pMMR. It aims to improve outcomes for patients with high-risk features.
ShanghaiAges 18–70 - NCT05972655RecruitingPhase 2
Testing shorter rectal radiation with chemotherapy plus immunotherapy
This Phase 2 study tests whether a shorter course of radiation, combined with chemotherapy (CAPOX) and an immunotherapy drug (tislelizumab), can control middle and low rectal cancer. It may also help people who strongly want to keep their anus, if the cancer and overall health fit the study rules.
Hanzhou, ZhejiangAges 18–75 - NCT07118527RecruitingPhase 3
New drug combo for untreated advanced stomach cancer
This trial tests a new combination of an anti-HER2 drug (SHR-A1811) plus chemotherapy and an immunotherapy (adebrelimab) for people with untreated advanced stomach cancer. It aims to see if this combination works better than standard treatment.
Shenyang, LiaoningAges 18–75 - NCT07294664RecruitingPhase 2
Drug combo trial for first treatment of advanced stomach cancer
This trial tests a combination of an immunotherapy drug (PD1/TGFβ), another targeted drug (SHR2554 or apatinib), and chemotherapy for people who have not yet been treated for advanced stomach cancer. The goal is to see if this combination works better than standard treatments.
Zhengzhou, HenanAges 18 years+ - NCT06068023Recruiting
Chemotherapy after surgery for ampullary cancer
This study tests whether giving chemotherapy after surgery (adjuvant chemotherapy) helps prevent ampullary cancer from coming back. It is for people who have had their ampullary cancer completely removed and are in reasonably good health.
Brescia, BSAges 18–100 - NCT07150949RecruitingPhase 2
Comparing two radiation schedules with chemotherapy and immunotherapy for rectal cancer
This study tests two different radiation regimens (long-course vs. short-course) combined with chemotherapy (CAPOX), an immunotherapy drug (PD-1 antibody), and a COX-2 inhibitor for people with MSS locally advanced rectal cancer. The goal is to see which approach works better in shrinking the tumor before surgery.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06787183RecruitingPhase 2
Short-course radiation with chemoimmunotherapy for rectal cancer that has spread to the liver
This trial tests whether combining short-course radiation with a chemotherapy regimen (CAPOX) and an immunotherapy drug (QL1706) can help treat rectal cancer that has spread to the liver. It is designed for patients who have not had any prior cancer treatment.
Fuzhou, FujianAges 18–75 - NCT06802666RecruitingPhase 2
Short radiation plus combo drugs for rectal cancer
This trial tests a new combination for rectal cancer that hasn't spread far: a short course of radiation followed by two drugs (AK112 and CAPOX). The goal is to shrink the tumor before surgery and possibly avoid more aggressive treatments.
HubeiAges 18–75 - NCT06840665RecruitingPhase 2
Radiation plus immunotherapy and chemo for rectal cancer
This trial combines a special type of radiation (MRI-guided adaptive radiotherapy) with an immunotherapy drug (PD-1 antibody) and chemotherapy (CAPOX) for locally advanced rectal cancer. The goal is to see if this combination can improve treatment outcomes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT03125980RecruitingPhase 3
Chemo timing before vs after colon cancer surgery
This Phase 3 study compares two schedules of a colon cancer chemo combination: starting before surgery or starting after surgery. It aims to see which timing helps people live longer and lowers cancer coming back.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05912075RecruitingPhase 1
New pre-surgery radiation plus ASTX660 for rectal cancer
This early-phase trial tests adding ASTX660 (a new drug) to pre-surgery radiation for locally advanced rectal cancer. It aims to improve control of the tumor before surgery, making it more likely that the surgeon can remove it with clear margins.
Lyon, RhöneAges 18 years+ - NCT06350006RecruitingPhase 1
Testing SHR-A1904 combinations for CLDN18.2-positive advanced tumors
This study tests an experimental drug combination for people with advanced solid tumors that have a specific protein called CLDN18.2. It aims to see if the combination works better than standard treatments.
Guangzhou, GuangdongAges 18–75 - NCT07327229RecruitingPhase 1/Phase 2
Study of ATG-022 plus pembrolizumab for stomach or GEJ cancer
This trial tests a new drug combo (ATG-022 plus pembrolizumab, with or without chemo) for people with advanced stomach or gastroesophageal junction cancer that has a specific protein (CLDN 18.2) and is HER2-negative and PD-L1-positive. It may be an option if you have not had certain prior treatments.
Hefei, AnhuiAges 18 years+
What Capox is being studied for
Conditions with recruiting Capox studies.
Common questions
- Are there clinical trials studying Capox?
- Yes. Clin2 currently lists 43 recruiting studies that include Capox, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Capox trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Capox an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Capox or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.